Is Entera Bio Ltd (ENTX) a Winner in the Biotechnology Industry? – InvestorsObserver

The 61 rating InvestorsObserver gives to Entera Bio Ltd (ENTX) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 69 percent of stocks in the Biotechnology industry, ENTXs 61 overall rating means the stock scores better than 61 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Entera Bio Ltd (ENTX) stock is trading at $1.90 as of 1:11 PM on Wednesday, Feb 10, a decline of -$0.03, or -1.55% from the previous closing price of $1.93. The stock has traded between $1.82 and $2.09 so far today. Volume today is 475,843 compared to average volume of 604,868.

Click Here to get the full Stock Score Report on Entera Bio Ltd (ENTX) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read the original here:
Is Entera Bio Ltd (ENTX) a Winner in the Biotechnology Industry? - InvestorsObserver

Where Does Polarityte Inc (PTE) Stock Fall in the Biotechnology Field? – InvestorsObserver

A rating of 33 puts Polarityte Inc (PTE) near the middle of the Biotechnology industry according to InvestorsObserver. Polarityte Inc's score of 33 means it scores higher than 33% of stocks in the industry. Polarityte Inc also received an overall rating of 39, putting it above 39% of all stocks. Biotechnology is ranked 23 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 39 means the stock is more attractive than 39 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Polarityte Inc (PTE) stock is trading at $1.27 as of 1:29 PM on Monday, Feb 8, a gain of $0.12, or 9.91% from the previous closing price of $1.16. The stock has traded between $1.19 and $1.32 so far today. Volume today is 9,264,669 compared to average volume of 12,177,284.

Click Here to get the full Stock Score Report on Polarityte Inc (PTE) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read the rest here:
Where Does Polarityte Inc (PTE) Stock Fall in the Biotechnology Field? - InvestorsObserver

YU and Montefiore Announce New BA/BS-MD Program with Einstein for High School Students – The Commentator – The Commentator

YU President Ari Berman and President and CEO of Montefiore Medicine Philip Ozuah signed a new agreement launching a joint YU-Albert Einstein College of Medicine BA/BS-MD program for high school graduates, according to an announcement made by YU on Jan. 19.

The new program, which is set to begin in 2022, will enable students to complete their undergraduate degree and continue directly into medical school at Einstein. Students apply for the program in their senior year of high school and are accepted to both schools, eliminating the separate application process usually necessary to progress from an undergraduate college to a medical school. This follows similar types of programs at other universities, such as the Sophie Davis Biomedical Education Program at the CUNY School of Medicine.

I have enjoyed working with Dr. Ari Berman to lay the groundwork for an exciting new chapter for Montefiore Medicine, Albert Einstein College of Medicine, and Yeshiva University, Ozuah told The Commentator.

According to YUs press release, this program is intended for highly qualified high school graduates ensuring their path to an excellent medical education and an impactful career in health care. Additionally, the press release noted that YU and Einstein established a task force to study the creation of additional joint academic and career-related programs in the fields of healthcare and health sciences. Provost and Vice President of Academic Affairs Dr. Selma Botman commented, This new era opens up potential for additional educational and research initiatives for our students.

Some current pre-med students, like Yona Berzon (SCW 23), were impressed with the program. This seems like such a brilliant program and an obvious choice for high schoolers who are serious about medicine, she said. Berzon, who is disappointed the program did not exist when she applied to college, also believes that this program will draw more students in who may not otherwise attend YU.

Most of the details of this new program such as how selective the program will be, eligibility for admissions, requirements that will need to be maintained once admitted and what happens if a student decided to drop out still need to be worked out. Botman shared that additional information on the program will be available in the coming months.

This partnership marks a significant renewal in YU and Einsteins partnership, which faltered in 2015 when YU turned over the leadership of Einstein to the Montefiore Health System.

Founded by YU in 1953, Einstein was created at a time when access to medical schools was generally restricted for Jews. Since its starting class of 56 students in 1955, Einstein has conferred 8,749 MD and 1,606 PhD degrees, and is currently ranked No. 40 in Best Medical Schools for Research and No. 43 in Best Medical Schools for Primary Care. In 1963, Einstein first established its affiliation with Montefiore Medical Center, which became Einsteins university hospital and academic medical center in 2009. However, it was not until February 2015 that YU announced the transfer of ownership of Einstein to the Montefiore Health System, in order to eliminate a massive deficit from the university's financial statements. The medical school was estimated to account for two-thirds of YUs annual operating deficits, which reached $100 million at the time of the announcement.

The agreement between YU and Montefiore was finalized on Sept. 9, 2015. Details of this transaction remained unclear at the time, as YU and Montefiore Health System declined to share any financial details of the deal, but documents obtained by The Forward show that YU transferred hundreds of millions of dollars in assets to Montefiore, including real estate and a portion of its endowment.

While financial and operational control of Einstein transferred over to Montefiore, which already operated Einsteins university hospital, YU continued to be the degree-granting authority until 2019, when the New York Board of Regents granted Einstein independent degree-granting jurisdiction. As of publication, it is unclear how, if at all, the announcement of this new program will affect the YU-Einstein partnership going forward.

However, in an email sent to the student body on Feb. 4, Berman wrote, This exciting new chapter in our relationship with Einstein further establishes opportunities for our students to attend and benefit from the incredible world-class research of our affiliate medical school.

--

Photo Caption: Montefiore Medicine President Philip Ozuah (left) and YU President Ari Berman (right)Photo Credit: Yeshiva University

Read the rest here:
YU and Montefiore Announce New BA/BS-MD Program with Einstein for High School Students - The Commentator - The Commentator

LPSS career center expands medical career course options; new course opening this fall – The Advocate

The novel coronavirus pandemic has increased demand for certified medical providers in key areas, and the Lafayette Parish School Systems W.D. and Mary Baker Smith Career Center is expanding its medical certification offerings to help students capitalize on job opportunities post-graduation.

Principal Holly Boffy said the career center will begin offering a new medical assistant program in the fall, in addition to an EMT program launched this August and an overhauled nursing program. The nursing program, originally a certified nursing assistant class, has been swapped to a patient care technician class, she said.

The transition was in the works before Boffy, whos been with the center for roughly seven months, took over, but the principal said one reason for the switch is that the patient care technician and medical assistant courses together allow more students the opportunity to earn medical credentials.

Previously, the EMT course was exclusive to Lafayette High Schools Health Careers Magnet Academy; the Lafayette High course will remain in place, Boffy said.

Launching a program revamp during the pandemic is ambitious, but Boffy said it was important to the career center and the district that current juniors and seniors dont miss out on career advancement while job opportunities exist. The goal is to provide as many students with options for advancement as possible, she said.

While a lot of students when they graduate from high school plan on going to college, some go to college and find theyre not successful or some of them need to have a job that pays more than minimum wage to even help them further their education. I think its good for all of our students to have opportunities to get industry based credentials so they graduate from school, can get that good first job and begin to build a career, the principal said.

Each course is open to juniors and seniors. The courses are limited because of age restrictions set on the certification exams, Boffy said. In addition to potential certification, the courses also count for three credit hours and will count toward graduation requirements.

The Lafayette Parish School System is transitioning hybrid students to campuses for in-person learning shortly after the Mardi Gras break, acc

This year, there are six students enrolled in the EMT course and 45 students in the patient care technician courses, Boffy said. The first months of the new courses have been about adjusting the curricula, gathering equipment and materials, registering with necessary state boards and seeking guidance from partners, like Acadian Ambulance and the St. Landry Parish School District, which itself made the switch from the CNA to patient care technician and medical assistant programs, she said.

So far, the student response has been positive, the principal said.

All of the juniors that we have have said theyre returning for their senior year in the program. I think thats a great indication we made the right choice, Boffy said.

Spencer Sonnier, the career centers EMT instructor, passed his EMT certification last summer after previously earning his emergency medical responder certification. Fresh off the test, Sonnier said hes able to coach the students on how to approach the written and practical application portions of the certification exam. Its not just about knowing the material, but about knowing how to reason and apply the knowledge in different scenarios, he said.

Course topics include CPR, how to supply supplemental oxygen, how to fashion a sling, how to read vitals, how to mobilize a broken long bone and how to stabilize someone with a potential spinal injury, Sonnier said.

Sonnier, an athletic trainer at Northside High School, said his emergency medical skills strengthen his ability to provide the best care to players in all situations.

cole St. Landry, a new French immersion charter school in St. Landry Parish, is accepting applications for its inaugural semester, planning a

It helps me in my profession see it from a different angle and be able to be a better athletic trainer, and vice versa, athletic training has helped me be a better EMT. It adds another viewpoint on situations, he said.

The usefulness of an EMT certification is broad and career options arent limited to working on an ambulance. EMTs work with SWAT teams, in fire departments and in the oil field, among other areas, and students interested in nursing school or medical school can get valuable experience and a resume boost from working as an EMT, Sonnier said.

Earning the certification in high school can either give students a head start toward those goals, or help students rule out a planned career option with less risk, the teacher said.

It saves time and money for the student if they take it while theyre in high school. The high school pays for their learning, as opposed to if they wanted to take it after graduation, then they would have to pay for their learning. And then just the time, because once they graduate theyre ready to go instead of taking the traditional class that could take six months to a year, Sonnier said.

Read more:
LPSS career center expands medical career course options; new course opening this fall - The Advocate

Donation to Canadas smallest medical school will help train northern doctors – Yahoo News Canada

The Canadian Press

The latest numbers of confirmed COVID-19 cases in Canada as of 7:30 p.m. ET on Saturday Feb. 13, 2021. There are 823,353 confirmed cases in Canada. _ Canada: 823,353 confirmed cases (36,656 active, 765,469 resolved, 21,228 deaths).*The total case count includes 13 confirmed cases among repatriated travellers. There were 3,047 new cases Saturday. The rate of active cases is 96.45 per 100,000 people. Over the past seven days, there have been a total of 21,868 new cases. The seven-day rolling average of new cases is 3,124. There were 66 new reported deaths Saturday. Over the past seven days there have been a total of 526 new reported deaths. The seven-day rolling average of new reported deaths is 75. The seven-day rolling average of the death rate is 0.2 per 100,000 people. The overall death rate is 55.86 per 100,000 people. There have been 22,922,357 tests completed. _ Newfoundland and Labrador: 686 confirmed cases (288 active, 394 resolved, four deaths). There were 26 new cases Saturday. The rate of active cases is 55.16 per 100,000 people. Over the past seven days, there have been a total of 271 new cases. The seven-day rolling average of new cases is 39. There have been no deaths reported over the past week. The overall death rate is 0.77 per 100,000 people. There have been 157,097 tests completed. _ Prince Edward Island: 114 confirmed cases (two active, 112 resolved, zero deaths). There were zero new cases Saturday. The rate of active cases is 1.25 per 100,000 people. Over the past seven days, there have been a total of one new cases. The seven-day rolling average of new cases is zero. There have been no deaths reported over the past week. The overall death rate is zero per 100,000 people. There have been 95,793 tests completed. _ Nova Scotia: 1,592 confirmed cases (10 active, 1,517 resolved, 65 deaths). There were two new cases Saturday. The rate of active cases is 1.02 per 100,000 people. Over the past seven days, there have been a total of eight new cases. The seven-day rolling average of new cases is one. There have been no deaths reported over the past week. The overall death rate is 6.64 per 100,000 people. There have been 300,593 tests completed. _ New Brunswick: 1,398 confirmed cases (161 active, 1,215 resolved, 22 deaths). There were 16 new cases Saturday. The rate of active cases is 20.6 per 100,000 people. Over the past seven days, there have been a total of 61 new cases. The seven-day rolling average of new cases is nine. There were zero new reported deaths Saturday. Over the past seven days there have been a total of two new reported deaths. The seven-day rolling average of new reported deaths is zero. The seven-day rolling average of the death rate is 0.04 per 100,000 people. The overall death rate is 2.82 per 100,000 people. There have been 223,163 tests completed. _ Quebec: 275,880 confirmed cases (10,533 active, 255,146 resolved, 10,201 deaths). There were 1,049 new cases Saturday. The rate of active cases is 122.84 per 100,000 people. Over the past seven days, there have been a total of 6,903 new cases. The seven-day rolling average of new cases is 986. There were 28 new reported deaths Saturday. Over the past seven days there have been a total of 202 new reported deaths. The seven-day rolling average of new reported deaths is 29. The seven-day rolling average of the death rate is 0.34 per 100,000 people. The overall death rate is 118.97 per 100,000 people. There have been 5,868,164 tests completed. _ Ontario: 284,887 confirmed cases (12,343 active, 265,893 resolved, 6,651 deaths). There were 1,300 new cases Saturday. The rate of active cases is 83.77 per 100,000 people. Over the past seven days, there have been a total of 8,169 new cases. The seven-day rolling average of new cases is 1,167. There were 19 new reported deaths Saturday. Over the past seven days there have been a total of 168 new reported deaths. The seven-day rolling average of new reported deaths is 24. The seven-day rolling average of the death rate is 0.16 per 100,000 people. The overall death rate is 45.14 per 100,000 people. There have been 10,121,997 tests completed. _ Manitoba: 30,687 confirmed cases (1,628 active, 28,193 resolved, 866 deaths). There were 99 new cases Saturday. The rate of active cases is 118.03 per 100,000 people. Over the past seven days, there have been a total of 529 new cases. The seven-day rolling average of new cases is 76. There were zero new reported deaths Saturday. Over the past seven days there have been a total of 24 new reported deaths. The seven-day rolling average of new reported deaths is three. The seven-day rolling average of the death rate is 0.25 per 100,000 people. The overall death rate is 62.79 per 100,000 people. There have been 504,191 tests completed. _ Saskatchewan: 26,389 confirmed cases (1,950 active, 24,085 resolved, 354 deaths). There were 244 new cases Saturday. The rate of active cases is 165.44 per 100,000 people. Over the past seven days, there have been a total of 1,180 new cases. The seven-day rolling average of new cases is 169. There were four new reported deaths Saturday. Over the past seven days there have been a total of 18 new reported deaths. The seven-day rolling average of new reported deaths is three. The seven-day rolling average of the death rate is 0.22 per 100,000 people. The overall death rate is 30.03 per 100,000 people. There have been 537,172 tests completed. _ Alberta: 128,540 confirmed cases (5,271 active, 121,494 resolved, 1,775 deaths). There were 305 new cases Saturday. The rate of active cases is 119.2 per 100,000 people. Over the past seven days, there have been a total of 2,124 new cases. The seven-day rolling average of new cases is 303. There were 15 new reported deaths Saturday. Over the past seven days there have been a total of 70 new reported deaths. The seven-day rolling average of new reported deaths is 10. The seven-day rolling average of the death rate is 0.23 per 100,000 people. The overall death rate is 40.14 per 100,000 people. There have been 3,277,825 tests completed. _ British Columbia: 72,750 confirmed cases (4,454 active, 67,008 resolved, 1,288 deaths). There were zero new cases Saturday. The rate of active cases is 86.52 per 100,000 people. Over the past seven days, there have been a total of 2,606 new cases. The seven-day rolling average of new cases is 372. There were zero new reported deaths Saturday. Over the past seven days there have been a total of 42 new reported deaths. The seven-day rolling average of new reported deaths is six. The seven-day rolling average of the death rate is 0.12 per 100,000 people. The overall death rate is 25.02 per 100,000 people. There have been 1,807,331 tests completed. _ Yukon: 71 confirmed cases (one active, 69 resolved, one deaths). There was one new case Saturday. The rate of active cases is 2.38 per 100,000 people. Over the past seven days, there has been one new case. The seven-day rolling average of new cases is zero. There have been no deaths reported over the past week. The overall death rate is 2.38 per 100,000 people. There have been 7,854 tests completed. _ Northwest Territories: 38 confirmed cases (six active, 32 resolved, zero deaths). There were zero new cases Saturday. The rate of active cases is 13.29 per 100,000 people. Over the past seven days, there have been a total of six new cases. The seven-day rolling average of new cases is one. There have been no deaths reported over the past week. The overall death rate is zero per 100,000 people. There have been 13,038 tests completed. _ Nunavut: 308 confirmed cases (nine active, 298 resolved, one deaths). There were five new cases Saturday. The rate of active cases is 22.87 per 100,000 people. Over the past seven days, there have been a total of nine new cases. The seven-day rolling average of new cases is one. There have been no deaths reported over the past week. The overall death rate is 2.54 per 100,000 people. There have been 8,063 tests completed. This report was automatically generated by The Canadian Press Digital Data Desk and was first published Feb. 14, 2021. This report by The Canadian Press was first published Feb. 14, 2021 The Canadian Press

View post:
Donation to Canadas smallest medical school will help train northern doctors - Yahoo News Canada

Of All Things: Medicine names, old and new – Montgomery Newspapers

Words interest me. Ive been reading them since I was five years old or so, and working with them for profit ever since I sold my first writing while I was in high school.

Which is why I wonder who invents all those unusual names that are hung on brands of medicine.

I see them in advertising in magazines, especially in ones about travel or gardening or entertainment, aimed at a middle-aged audience. They are astonishingly meaningless.

I jotted down a few of them:Cequa, Dovoto, Fanaft, Isbrance, Keytruda, Nexletol, Nuplazid, Prevagen, Rinvoq, Rybelsis, Skyrizi, and XiiDRA.

There is no way most of us could tell that Cequa treats dry eyes, and Fanaft is for schizophrenia. Maybe they teach it in medical school like a foreign language.

It was always like that in a way, but the names on most medicine bottles were not in impossible language when I was a little boy. So I looked into some of the medicines then inflicted on me.

Castor Oil, a nasty-tasting laxative dreaded by little kids, was labeled in plain English, and still is. You can buy a bottle for a few bucks at Walmart. You can buy a castor bean plant and grow your own. And there are places where you can buy a gallon for about 25 bucks. I dont want to think about a gallon.

Aspirin is short foracetylsalicylic acid, which GermanchemistCharles FredericGerhardtcreated in 1853. By 1899, the Bayerfirmhad named it Aspirin and sold it around the world.The wordAspirinwas Bayer's brand name, but, its rights to the use itwere lost in many countries.

You can still buy Father Johns Cough Syrup at Walmart. Another regular potion when I was a kid is harder to find these days.

It started on May 12, 1868, when a patent was granted to Dr. Samuel Pitcher (1824-1907) of Barnstable, Massachusetts, for a cathartic thats ingredients included sodium bicarbonate, but also essence of wintergreen, dandelion, sugar and water. The remedy was first sold as Pitcher'sCastoria.

Read more from the original source:
Of All Things: Medicine names, old and new - Montgomery Newspapers

Covid-19 Live News and Updates – The New York Times

Heres what you need to know:Genomic sequencing can detect and track virus variants, but the United States is sequencing relatively few coronavirus test samples. Lab technicians at Duke University prepared samples for sequencing earlier this month.Credit...Pete Kiehart for The New York Times

As Americans anxiously watch the spread of coronavirus variants that were first identified in Britain and South Africa, scientists are finding a number of new variants that seem to have originated in the United States and many of them may pose the same kind of extra-contagious threat.

In a study posted on Sunday, a team of researchers reported seven growing lineages of the coronavirus, spotted in states across the country. All have gained a mutation at the exact same spot in their genes.

Theres clearly something going on with this mutation, said Jeremy Kamil, a virologist at Louisiana State University Health Sciences Center and a co-author of the new study.

Its not clear yet whether this shared mutation makes the variants more contagious, but because it appears in a gene that influences how the virus enters human cells, the scientists are highly suspicious.

I think theres a clear signature of an evolutionary benefit, Dr. Kamil said.

Its not unusual for different genetic lineages to independently evolve in the same direction. Charles Darwin recognized convergent evolution in animals. Virologists have found that it happens with viruses, too. As the coronavirus branches into new variants, researchers are observing Darwins theory of evolution in action every day.

Its difficult to answer even basic questions about how prevalent the new variants are in the United States because the country sequences genomes from less than 1 percent of coronavirus test samples. The researchers found examples scattered across much of the country, but they cant tell where they first arose.

Its also hard to say whether the variants are spreading now because they are more contagious, or for some other reason, like holiday travel or superspreader events.

Scientists say the mutation could plausibly affect how easily the virus gets into human cells. But Jason McLellan, a structural biologist at the University of Texas at Austin who was not involved in the study, cautioned that the way that the coronavirus unleashes its harpoons was still fairly mysterious.

Its tough to know what these substitutions are doing, he said of the mutations. It really needs to be followed up with some additional experimental data.

Vaccinations are picking up pace. The spread of the coronavirus in the United States has slowed drastically. The Centers for Disease Control and Prevention is urging K-12 schools to reopen safely and as soon as possible.

But just as states are again lifting mask-wearing mandates and loosening restrictions, experts fear that more contagious variants could undo all that progress.

That threat seems only to grow as researchers learn more. British government scientists now believe the more contagious variant that is ravaging Britain is also likely to be deadlier than earlier versions of the virus, according to a document posted on a government website on Friday. An earlier assessment on a smaller scale warned last month that there was a realistic possibility the variant was more lethal.

The variant, also known as B.1.1.7, is spreading rapidly in the United States, doubling roughly every 10 days, another recent study found.

In line with an earlier warning from the C.D.C., the study predicted that by March the variant could become the dominant source of coronavirus infection in the United States, potentially bringing a surge of new cases and increased risk of death.

Beyond that, scientists reported on Sunday that they have begun to spot more new variants that seem to have emerged in the U.S. and are concerned that they may spread more readily than earlier versions.

Vaccine distribution is accelerating the U.S. is now averaging about 1.66 million doses a day, well above the Biden administrations target of 1.5 million but B.1.1.7 has a worrisome mutation that could make it harder to control with vaccines, a Public Health England study found this month.

The variant has spread to at least 82 countries, and is being transmitted 35 percent to 45 percent more easily than other variants in the United States, scientists recently estimated. Most people who catch the virus in Britain these days are being infected by that variant.

The British research on B.1.1.7s lethality did come with caveats, and the reasons for the variants apparently elevated death rate are not entirely clear. Some evidence suggests that people infected with the variant may have higher viral loads, a feature that could not only make the virus more contagious but also potentially undermine the effectiveness of certain treatments.

But government scientists were relying on studies that examined a small proportion of overall deaths. They also struggled to account for the presence of underlying illnesses in people infected with the new variant, and for whether the cases originated in nursing homes.

Bill Hanage, an epidemiologist at Harvard University, said that although we do need to have a degree of caution in looking at the findings, its perfectly reasonable to think that this is something serious I am certainly taking it seriously.

Its pretty clear we have something which is both more transmissible and is more worrying if people become infected, he said.

Angela Rasmussen, a virologist at Georgetown University, said relaxing restrictions now would be courting disaster. She urged Americans to be extra vigilant about mask wearing, distancing and avoiding enclosed spaces.

You dont want to get any variant, Dr. Rasmussen said, but you really dont want to get B.1.1.7.

The United States confirmed its first case of the B.1.1.7 variant on Dec. 29. Unlike Britain, it has been conducting little of the genomic sequencing necessary to track the spread of new variants that have caused concern, though the Biden administration has vowed to do more.

On Friday, for the fifth time in six days, the number of new virus cases reported in the United States dipped below 100,000 far less than the countrys peak of more than 300,000 reported on Jan. 8.

As the number of virus cases and hospitalizations has fallen, the Republican governors of Montana, Iowa, North Dakota and Mississippi have recently ended statewide mask-wearing mandates. In New York, Gov. Andrew M. Cuomo, a Democrat, has allowed indoor dining to resume at 25 percent capacity, though experts have repeatedly warned that maskless activities, such as eating, in enclosed spaces are high-risk.

Although virus case numbers are moving in the right direction, the loosening of restrictions has unnerved experts like Saskia Popescu, an epidemiologist at George Mason University in Virginia.

Now more than ever, with novel variants, we need to be strategic with these reopening efforts and be slow and not rush things, she said.

The director of the Centers for Disease Control, Dr. Rochelle Walensky, tried on Sunday to build support for reopening schools, even in districts with high infection rates and before vaccinating teachers, political sticking points for the Biden administration.

In a round of appearances on the morning news shows, Dr. Walensky promoted her agencys new guidelines for schools, seeking to build confidence that the Biden administrations strategy could satisfy teachers and parents alike and fulfill the new presidents promise to reopen schools by his 100th day in office.

We hadnt previously had the science in order to inform how to open safely, Dr. Walensky said on Fox News Sunday. We didnt have the data, and prior we didnt have any guidance as to how to do it safely, so we are really anticipating with this guidance emerging, that schools will be able to start reopening.

She reiterated her earlier, controversial statement at a news briefing that scientific data supported the idea of reopening schools before teachers were vaccinated but she also noted that the C.D.C.s advisory panel on vaccines recommended that states consider teachers to be essential workers, placing them high on the priority list.

The Biden administration is juggling demands to open schools as soon as possible with teachers concerns about safety. Earlier this month, teachers unions objected to Dr. Walenskys comment about teachers not needing to be vaccinated before schools reopened. The comment also drew a rebuke from the White House press secretary, Jen Psaki, who said Dr. Walenskys remark was made in her personal capacity.

The guidelines issued on Friday offered a chance for a reset, by outlining strict and expensive safety measures, like cleaning, mask wearing, contact tracing, frequent testing and social distancing.

But on Sunday, Dr. Walensky acknowledged that few schools were currently up to the task, without a significant infusion of federal funds.

Not all schools are able to do all of those things right now, she said on CNN, and many of those schools are in red zones, referring to communities with high infection rates. We need to do the work to get all of those mitigation strategies up and running in all of the schools.

transcript

transcript

Its a very important day for us, weve been waiting for it, this pandemic took a great toll. Weve had a lot of cases, a lot of fatalities in Lebanon. So were really looking forward to the vaccine to hopefully see some light at the end of the tunnel. Privileged. Excited. Happy that this is happening, that it is happening to Lebanon. A good thing for once. Its working. And I look forward to everybody being able to get the chance to get it too.

BEIRUT, Lebanon Lebanon began vaccinating its citizens against Covid-19 on Sunday, offering a rare glimmer of hope in a country suffering badly from several overlapping crises, just one of which is the pandemic.

The first shot was administered to the director of the intensive care unit at the lead government hospital fighting the pandemic. The second was given to a famous 93-year-old comedian.

The vaccination drive began after Lebanon received its first batch of 28,500 doses of the Pfizer-BioNTech vaccine. Using $34 million in financing from the World Bank, Lebanon is buying enough doses to vaccinate about two million people, roughly one-third of its population. Millions more doses are expected to arrive in the spring and summer through a United Nations program and commercial sources.

Lebanons worst coronavirus surge peaked in mid-January, when the country was averaging more than 4,800 newly reported cases a day, according to a New York Times database; the average has since fallen somewhat, to about 2,700 a day. Some 337,000 people in Lebanon almost 5 percent of the population are now known to have had the virus, and more than 3,900 have died.

To try to drive the numbers down, the government imposed a very strict lockdown in mid-January, with a 24-hour curfew and widespread shop closures. It eased the restrictions slightly last week, but the curfew largely remains in effect.

The suffering caused by the pandemic has been compounded by a political crisis that has left Lebanon without an effective government for six months, and a financial crisis that has drastically weakened the local currency, making imported medicines, food and other products more expensive.

A huge explosion in the port of Beirut last August also made matters worse, heavily damaging four hospitals, killing 200 people and leaving thousands more wounded.

global roundup

transcript

transcript

These new cases pose questions our public health staff are working around the clock to answer. We dont yet have a complete picture of the potential source of the infection and spread, if any, beyond one household. And we are waiting for the genome sequencing and serology, both of which will provide important pieces of this puzzle. As of 11:59 p.m. tonight, Sunday, Feb. 14, Aukland will move to Level 3 for a period of three days, until midnight on Wednesday. The rest of New Zealand will move to Level 2 for the same period of time. The main thing we are asking people in Auckland to do is to stay home to avoid any risk of spread. That means staying in your bubble other than for essential personal movement. People should work from home unless that is not possible. If you go outside your home, please maintain physical distancing of two meters outside. Or if youre in a controlled environment where you know others present, one meter. Im asking New Zealanders to continue to be strong and be kind. I know we all feel the same way when this happens. We all get that sense of, not again. But remember, we have been here before. That means we know how to get out of this again. And that is together. If you know someone in Auckland, reach out, please check on them. And if youre in Auckland, please check on your neighbors, ensure theyre looked after and supported. And finally, as Ive said all the way through this, ultimately, please remember, we are going to be OK.

AUCKLAND, New Zealand Faced with the creeping threat of more infectious coronavirus variants, Australia and New Zealand have responded to a small number of cases with near-immediate regional lockdowns.

On Sunday night, as couples celebrating Valentines Day strolled arm-in-arm through central Auckland, Prime Minister Jacinda Ardern of New Zealand announced that the city would begin a three-day lockdown at midnight because of three unexplained positive test results in a single family. The rest of New Zealand would be subject to increased physical distancing requirements over the same period, she said.

Ms. Ardern said Monday that all three cases were the variant first detected in Britain, and that its higher transmissibility meant the government had been absolutely right to order the lockdown. Australia has also suspended quarantine-free travel with New Zealand for at least 72 hours over the new cases.

Separately, both countries said Monday that they had received their first shipments of the Pfizer vaccine.

New Zealand has had almost no virus-related restrictions since the fall, when it successfully eliminated the virus for a second time. Over all, the country has reported 2,330 coronavirus cases and 25 deaths, far fewer in proportion to its population than most other developed nations.

The Australian state of Victoria has also been placed in a short-term lockdown in response to a small outbreak, which began at a quarantine hotel and has grown to 16 cases. During the lockdown, which began at 11:59 p.m. Friday and is intended to last five days, most of Victorias six million people are not allowed to leave home except for limited periods of outdoor exercise or shopping. Professional tennis players who are in Melbourne, the state capital, for the Australian Open are considered essential workers and have been allowed to continue playing their matches, albeit without fans in attendance.

Like New Zealand, Australia has had relatively few infections and deaths, and acts aggressively at the first sign of new outbreaks. Similar snap lockdowns in the Australian cities of Perth and Brisbane were successful recently at quashing transmission.

Announcing the Auckland lockdown on Sunday, Ms. Ardern said, Our view is, youll have less regret if you move early and hard than if you leave it and it gets out of control.

In other news around the world:

The start of ski season in Italy is delayed, the health minister Roberto Speranza announced. Citing the spread of a coronavirus variant, Mr. Speranza said amateur skiing was forbidden through at least March 5, The Associated Press reported. Italys last ski season was halted as the country became a coronavirus epicenter last spring, and it hasnt restarted since then. This years closure is another blow to an industry that generates 1.2 billion euros, or $1.5 billion, in annual revenues.

Portugal, which until the last few days had been enduring one of the worlds worst coronavirus surges, has prolonged its Covid-19 state of emergency. The extension, until at least March 1, comes as new daily cases fell over the weekend to their lowest level since late December, while the latest daily death toll, 138, is the lowest since Jan. 11. Still, Portugals Covid-19 death toll now stands at 15,321. By comparison, Greece, which has a roughly equal population of about 10 million, has recorded 6,126 deaths.

Japan issued its first approval for a vaccine against the coronavirus on Sunday, saying that it would use the Pfizer-BioNTech vaccine to begin inoculating frontline health care workers this week. Japan has been slower than the United States and Europe to authorize any coronavirus vaccines, but it has also had the luxury of time. Public health measures have successfully kept case rates low and the countrys economy has suffered less than others. It showed a sharp rebound, growing 3 percent, in the last three months of 2020. But the growth was fragile and could easily be disrupted, analysts cautioned.

New Yorkers with chronic health conditions that made them newly eligible for the Covid-19 vaccine flooded a state website and call center Sunday morning, leaving many unable to immediately schedule appointments at mass vaccination centers.

State officials said on Sunday that 73,000 appointments had been scheduled as of 11:30 a.m., while 500,000 people went through an online eligibility screening tool needed to make appointments. Thousands were in virtual waiting rooms that can hold up to 8,000 people per vaccination site. Once those waiting rooms are full, people attempting to schedule appointments are told to try again later.

Richard Azzopardi, a senior adviser to Gov. Andrew M. Cuomo, said demand was high, but our infrastructure has remained up and intact. He said that the states ability to make appointments depended on the vaccine supply, which is steadily increasing.

Officials said the new criteria, which include chronic health conditions like obesity and hypertension, made four million more New Yorkers eligible for the Covid-19 vaccine. They join a growing number of people in the state who are eligible for the vaccine despite a shortage in supply.

Those who are now eligible include adults who have certain health conditions that may increase their risk of severe illness or death from the coronavirus. Aside from obesity and hypertension, other conditions that would qualify New Yorkers for the vaccine include pulmonary diseases and cancer, Mr. Cuomo announced this month. He also made pregnancy a qualifying condition.

Appointments for people who are in this group can be scheduled for as early as Monday, though most people will probably face a long wait because vaccine doses are scarce now. New Yorkers must provide proof of their condition with a doctors note, signed certification or medical documentation, Mr. Cuomo said.

While this is a great step forward in ensuring the most vulnerable among us have access to this lifesaving vaccine, its no secret that any time youre dealing with a resource this scarce, there are going to be attempts to commit fraud and game the systems, Mr. Cuomo said in a statement.

In New York State, about 10 percent of the population has received its first dose, according to data gathered by The New York Times. With the new criteria, about 11 million people are now eligible in the state, including people ages 65 and older, health care workers and teachers over half the state population.

New York City recently opened mass vaccination sites at Yankee Stadium in the Bronx and Citi Field in Queens to better reach communities hit hard by the virus. The state and federal government also announced last week that the Federal Emergency Management Agency would open vaccination sites at Medgar Evers College in Brooklyn and York College in Queens.

To check on eligibility and schedule an appointment, New Yorkers can complete a prescreening on the states website. They can also call the states vaccination hotline at 1-833-NYS-4VAX (1-833-697-4829) for more information about vaccine appointments.

Phila Lachaux, a 22-year-old business student in France, dreamed of striking out on her own in the live music industry. But the pandemic led to the loss of her part-time job as a waitress, and sent her back to live at her family home.

Now, struggling to envision a future after months of restrictions, Ms. Lachaux says that loneliness and despair seep in at night. I look at the ceiling, I feel a lump in my throat, she said. Ive never had so many suicidal thoughts.

With curfews, closures and lockdowns in Europe set to drag into the spring or even the summer, mental health professionals are growing increasingly alarmed about the deteriorating mental state of young people.

Last in line for vaccines and with schools and universities shuttered, young adults have borne many of the sacrifices made largely to protect older people, who are more at risk from severe infections.

Across the world, the young have lost economic opportunities, missed traditional milestones and forfeited relationships at a pivotal time for forming identity.

Many feel theyre paying the price not of the pandemic, but of the measures taken against the pandemic, said Dr. Nicolas Franck, the head of a psychiatric network in Lyon, France. In a survey of 30,000 people that he conducted last spring, young people ranked the lowest in psychological well-being, he said.

In Italy and in the Netherlands, some youth psychiatric wards have filled to record capacity. In France, professionals have urged the authorities to consider reopening schools to fight loneliness. And in Britain, some therapists said that they had counseled patients to break lockdown guidelines to cope.

In the United States, a quarter of 18- to 24-year-olds said they had seriously considered suicide, one report said. In Latin America and the Caribbean, a survey conducted by UNICEF of 8,000 young people found that more than a quarter had experienced anxiety and 15 percent depression.

We are in the midst of a mental health pandemic, and I dont think its treated with near enough respect, said Arkadius Kyllendahl, a psychotherapist in London who has seen the number of younger clients double in recent months.

If you are having thoughts of suicide, the following organizations can help.

In Britain, call Papyrus at +44 800 068 4141 (9am to midnight), or message Young Minds: text YM to 85258. You can also find a list of additional resources on Mind.org.

In France, call SOS Amiti at +33 9 72 39 40 50 (24/7) or Fil Sant Jeunes at +33 800 235 236 (9am to 11pm). Ameli has a list of additional resources.

In Italy, call Telefono Amico at +39 2 2327 2327 (10am to midnight) or Telefono Azzurro at +39 19696 (a webchat is also available).

A team of experts selected by the World Health Organization to investigate the origins of the coronavirus returned last week from Wuhan, China, site of the worlds first outbreak. Having broken the ice with Chinese scientists, the team plans to produce a joint report on the possible origins of the virus.

The two groups of scientists agreed to pursue some ideas that the Chinese government has been promoting, like the possibility that the virus was transported on frozen food. But the W.H.O. team also became frustrated by Chinas refusal to turn over raw data for analysis.

Peter Daszak, a member of the W.H.O. team and the president of EcoHealth Alliance in New York, is primarily concerned with the animal origins of the virus. A specialist in animal diseases and their spread to humans, Dr. Daszak has worked with the Wuhan Virology Institute, a collaboration that last year prompted the Trump administration to cancel a grant to his organization.

In an interview after his return to New York, he said that the visit had provided some new clues, which all of the scientists, Chinese and international, agreed most likely pointed to an animal origin within China or Southeast Asia. The scientists have largely discounted claims that the virus originated in a lab, saying that possibility was so unlikely that it was not worth further investigation.

He reflected on the atmosphere in Wuhan and his first glimpse of the seafood market where the initial outbreak occurred last year, although it was not the site of the first cases. He also said the path ahead would be straightforward scientifically, but not politically.

The W.H.O. investigation was the subject of a sharp exchange over the weekend between the U.S. and Chinese governments. Jake Sullivan, the national security adviser, said Saturday that the Biden administration had deep concerns about its early findings and how they were communicated.

It is imperative that this report be independent, with expert findings free from intervention or alteration by the Chinese government, he said in a statement.

In response, the Chinese government asked whether the United States could be considered a credible partner in the matter, having only recently rejoined the W.H.O. after withdrawing during the Trump administration.

What the U.S. has done in recent years has severely undermined multilateral institutions, including the W.H.O., and gravely damaged international cooperation on Covid-19, the Chinese Embassy in Washington said in a statement.

But the U.S., acting as if none of this had ever happened, is pointing fingers at other countries who have been faithfully supporting the W.H.O. and at the W.H.O. itself, it continued. With such a track record, how can it win the confidence of the whole world?

Austin Ramzy contributed reporting.

WHEELING, W.Va. After nearly a year in lockdown for the residents of Good Shepherd Nursing Home eating meals in their rooms, playing bingo through their television sets and isolating themselves almost entirely from the outside world their coronavirus vaccinations were finished and the hallways were slowly beginning to reawaken.

In a first, tentative glimpse at what the other side of the pandemic might look like, Betty Lou Leech, 97, arrived to the dining room early, a mask on her face, her hair freshly curled.

See original here:
Covid-19 Live News and Updates - The New York Times

COVID-19 and victim-blaming has made it more difficult to care for people living with HIV/AIDS | Opinion – NJ.com

By Perry N. Halkitis, Shobha Swaminathan and Travis Love

For the 1.2 million Americans living with HIV or AIDS, the ongoing COVID-19 pandemic continues to undermine their physical, mental, social, and economic wellbeing.

These impacts on health are exacerbated in Black and brown communities particularly Black sexual- and gender-minority men and women and Black cisgender women who are coping with the realities created by COVID-19, ongoing systemic discrimination, and a plethora of other social inequities that create additional vulnerabilities to their overall health.

The COVID-19 pandemic has derailed our efforts to bring an end to the HIV/AIDS epidemic, adding to the stigma, systems of oppression and structural racism that ultimately fuel the HIV/AIDS epidemic in our state and country.

We know all too well that stigma is one of the reasons why patients continue to experience trauma related to their HIV diagnosis. In fact, for many people living with HIV/AIDS, reliving the trauma of isolation while simultaneously fearing for their lives should they become infected with COVID-19 has had a synergistic effect.

As a result of the ongoing stigma surrounding HIV/AIDS, many people who become infected with this virus may not want to know their status, fearing rejection from family, friends, and sexual partners. In fact, for those already diagnosed, the stigma and resulting trauma can prevent many from continuing to seek adequate care, undermining their viral suppression and resulting in the progression of HIV. This can also lead to increased infectivity to sexual partners.

In the early days of HIV/AIDS, victim-blaming was common and those who developed a detectable number of antibodies in their blood were categorized as either innocent victims (i.e. children and hemophiliacs) or immoral beings who through their actions brought the disease upon themselves (i.e. gay men and injection drug users).

We believe that stigma is the driving force behind the health disparities that continue to put people at risk for HIV/AIDS. In order to end the HIV/AIDS epidemic, we must ensure more access to care and cultivate an ecosystem that combats systemic racism, homophobia, and transphobia.

We must call on the federal government to fund and tackle gaps in care and to prioritize care for individuals who are vulnerable to both COVID-19 and HIV/AIDS, who are too often Black and brown people.

It is very possible to envision a world free from HIV, given our current medical advances in the form of preventative medication, PrEP, and effective antiretroviral therapy (ART), which when dosed properly creates a zero probability that an HIV-positive person can infect someone else.

What we need now, is a vaccine. After 30 years of research, a new clinical study, MOSAICO, shows promise and offers hope. The Rutgers New Jersey Medical School Clinical Research Center (NJMS CRC) is currently seeking volunteers who are queer, gender non-conforming, and transgender to screen and enroll in the study. The research team also facilitates workshops to reduce vaccine hesitancy and to raise research literacy.

Yet, medications are not enough. While novel therapeutics remain key, behavioral interventions and social acceptance are essential for their success. By using a status neutral approach, we will stop the forced differentiation of HIV positive and negative people. This approach is simple: a person is ensured access to care if they are HIV positive. If a person is HIV negative, they are given access to preventative medications such as PrEP.

Practicing a status neutral approach can repair the schism that has existed for far too long between HIV-positive and HIV-negative populations. Our goal is to assure that everyone has a right to good health.

Gov. Phil Murphy has shown how deeply he understands and how passionately he cares about the structural drivers of disease. Now we must act. We cannot let the HIV/AIDS epidemic continue to take a backseat to pressing health care issues of the moment. As we continue to raise awareness, we are calling on New Jerseys Legislative leadership to enact the policies developed by Governor Murphys Statewide Task Force to End the HIV Epidemic.

We all need to raise our voices together to end this epidemic. The public can also make a difference by urging our elected officials to:

To learn more, join Rutgers School of Public Health and Rutgers New Jersey Medical School as we strive to raise awareness of a Neutral Nation with a series of engaging events from February 17 to 20.

Dr. Perry N. Halkitis is dean and director of the Center for Health, Identity Behavior & Prevention Studies (CHIBPS) at the Rutgers School of Public Health. Dr. Halkitis also was a member of both the New Jersey and New York Ending the HIV Epidemic planning groups.

Dr. Shobha Swaminathan is an associate professor of medicine at Rutgers New Jersey Medical School and the Medical Director of the infectious diseases practice at University Hospital in Newark. She was a principal investigator of Modernas COVID-19 vaccine trial in Newark.

Travis Love is a community educator who has served as a public health representative at Rutgers New Jersey Medical School since 2016.

Our journalism needs your support. Please subscribe today to NJ.com.

Heres how to submit an op-ed or Letter to the Editor. Bookmark NJ.com/Opinion. Follow us on Twitter @NJ_Opinion and on Facebook at NJ.com Opinion. Get the latest news updates right in your inbox. Subscribe to NJ.coms newsletters.

Read more from the original source:
COVID-19 and victim-blaming has made it more difficult to care for people living with HIV/AIDS | Opinion - NJ.com

The Telling Numbers: How COVID-19 has Hit Black Residents in NJ – Jersey City Times

Higher impact of the disease is associated with existing health factors as well as social factors

This story was written and produced by NJ Spotlight. It is being republished under a special NJ News Commons content-sharing agreement related to COVID-19 coverage. To read more, visit njspotlight.com.

Full story link HERE.

By Colleen ODea

More evidence of COVID-19s disparate impact on New Jerseys African Americans can be found in an analysis by state health officials and a study by Rutgers University professors.

The state Department of Health adjusted cases, hospitalizations and deaths from the disease caused by the novel coronavirus for age and found the rate of infection among Black residents exceeded that of white residents, 4,181 per 100,000 compared with 3,332. African Americans were more than twice as likely as whites to be hospitalized from COVID-19 (810 per 100,000 versus 303) or to die from the disease (267 per 100,000 versus 120). Earlier this month, death data for 2020 showed COVID-19 was the number one killer of Blacks in New Jersey, with one of five African American deaths attributed to the disease and related conditions.

Health officials have noted the disparate impact the virus was having on Black and brown communities since early in the pandemic. The states COVID-19information portalbreaks out cases, hospitalizations and deaths by race. The state health commissioner typically relates some of this information during her briefings on the pandemic.

A recent study by a group of Rutgers University researchers published in theJournal of Racial and Ethnic Health Disparities found that COVID-19 mortality racial disparities in the U.S. are associated with such social factors as income, education and internet access and highlights the need for public-health policies that address structural racism.

The researchers looked at the association between COVID-19 cases and deaths in 2,026 U.S. counties from January to October 2020 and social determinants of health that can raise the risk for infection and death. They also looked at factors known or thought to impact COVID-19 outcomes, including the counties population density and such health factors as obesity, diabetes, chronic obstructive pulmonary disease and high blood pressure.

The study found that a higher rate in a countys percent of Black residents, uninsured adults, low birth-weight infants, adults without a high school diploma, incarceration rate and households without internet increased that countys COVID-19 death rates during the period examined.Counties that were the most deprived socioeconomically had a 67% increase in the COVID-19 death rate. Michelle DallaPiazza, lead author of the study and an associate professor at Rutgers New Jersey Medical School, said the percent of households without internet which provides updated knowledge of the pandemic and allows remote working and learning and the percentage of adults without a high school diploma were the factors most associated with a countys COVID-19 death rate.

The findings are consistent with historical health inequities in marginalized populations, particularly Black Americans, DallaPiazza said. This adds to the extensive literature on racial health disparities that demonstrate that social and structural factors greatly influence health outcomes, and this is particularly true when it comes to COVID-19.

Dr. Robert Johnson, dean of the Rutgers New Jersey Medical School and interim dean of Rutgers Robert WoodJohnson Medical School, said it is well-known that certain factors influence the way diseases like COVID-19 impact African Americans and others and policymakers need to make greater efforts to change these.

Theyre adversely affected by poverty, Johnson said. Theyre adversely affected by the environment they live in, adversely affected by poor nutrition. All these things need to be changed. Every time we have a severe chronic illness this is the outcome we get because the health disparities are real.

Header: Photo by Maria Oswalt on Unsplash

See the original post:
The Telling Numbers: How COVID-19 has Hit Black Residents in NJ - Jersey City Times

Virus may never go away but could change into mild annoyance – Sumter Item

NEW DELHI (AP) What if COVID-19 never goes away?

Experts say it's likely that some version of the disease will linger for years. But what it will look like in the future is less clear.

Will the coronavirus, which has already killed more than 2 million people worldwide, eventually be eliminated by a global vaccination campaign, like smallpox? Will dangerous new variants evade vaccines? Or will the virus stick around for a long time, transforming into a mild annoyance, like the common cold?

Eventually, the virus known as SARS-CoV-2 will become yet "another animal in the zoo," joining the many other infectious diseases that humanity has learned to live with, predicted Dr. T. Jacob John, who studies viruses and was at the helm of India's efforts to tackle polio and HIV/AIDS.

But no one knows for sure. The virus is evolving rapidly, and new variants are popping up in different countries. The risk of these new variants was underscored when Novavax Inc. found that the company's vaccine did not work as well against mutated versions circulating in Britain and South Africa. The more the virus spreads, experts say, the more likely it is that a new variant will become capable of eluding current tests, treatments and vaccines.

For now, scientists agree on the immediate priority: Vaccinate as many people as quickly as possible. The next step is less certain and depends largely on the strength of the immunity offered by vaccines and natural infections and how long it lasts.

"Are people going to be frequently subject to repeat infections? We don't have enough data yet to know," said Jeffrey Shaman, who studies viruses at Columbia University. Like many researchers, he believes chances are slim that vaccines will confer lifelong immunity.

If humans must learn to live with COVID-19, the nature of that coexistence depends not just on how long immunity lasts, but also how the virus evolves. Will it mutate significantly each year, requiring annual shots, like the flu? Or will it pop up every few years?

This question of what happens next attracted Jennie Lavine, a virologist at Emory University, who is co-author of a recent paper in Science that projected a relatively optimistic scenario: After most people have been exposed to the virus either through vaccination or surviving infections the pathogen "will continue to circulate, but will mostly cause only mild illness," like a routine cold.

While immunity acquired from other coronaviruses like those that cause the common cold or SARS or MERS wanes over time, symptoms upon reinfection tend to be milder than the first illness, said Ottar Bjornstad, a co-author of the Science paper who studies viruses at Pennsylvania State University.

"Adults tend not to get very bad symptoms if they've already been exposed," he said.

The prediction in the Science paper is based on an analysis of how other coronaviruses have behaved over time and assumes that SAR-CoV-2 continues to evolve, but not quickly or radically.

The 1918 flu pandemic could offer clues about the course of COVID-19. That pathogen was an H1N1 virus with genes that originated in birds, not a coronavirus. At the time, no vaccines were available. The U.S. Centers for Disease Control and Prevention estimates that a third of the world's population became infected. Eventually, after infected people either died or developed immunity, the virus stopped spreading quickly. It later mutated into a less virulent form, which experts say continues to circulate seasonally.

"Very commonly the descendants of flu pandemics become the milder seasonal flu viruses we experience for many years," said Stephen Morse, who studies viruses at Columbia University.

It's not clear yet how future mutations in SARS-CoV-2 will shape the trajectory of the current disease.

As new variants emerge some more contagious, some more virulent and some possibly less responsive to vaccines scientists are reminded how much they don't yet know about the future of the virus, said Mark Jit, who studies viruses at the London School of Hygiene and Tropical Medicine.

"We've only known about this virus for about a year, so we don't yet have data to show its behavior over five years or 10 years," he said.

Of the more than 12 billion coronavirus vaccine shots being made in 2021, rich countries have bought about 9 billion, and many have options to buy more. This inequity is a threat since it will result in poorer countries having to wait longer for the vaccine, during which time the disease will continue to spread and kill people, said Ian MacKay, who studies viruses at the University of Queensland.

That some vaccines seem less effective against the new strains is worrisome, but since the shots provide some protection, vaccines could still be used to slow or stop the virus from spreading, said Ashley St. John, who studies immune systems at Duke-NUS Medical School in Singapore.

Dr. Gagandeep Kang, an infectious diseases expert at Christian Medical College at Vellore in southern India, said the evolution of the virus raises new questions: At what stage does the virus become a new strain? Will countries need to re-vaccinate from scratch? Or could a booster dose be given?

"These are questions that you will have to address in the future," Kang said.

The future of the coronavirus may contrast with other highly contagious diseases that have been largely beaten by vaccines that provide lifelong immunity such as measles. The spread of measles drops off after many people have been vaccinated.

But the dynamic changes over time with new births, so outbreaks tend to come in cycles, explained Dr. Jayaprakash Muliyil, who studies epidemics and advises India on virus surveillance.

Unlike measles, kids infected with COVID-19 don't always exhibit clear symptoms and could still transmit the disease to vulnerable adults. That means countries cannot let their guard down, he said.

Another unknown is the long-term impact of COVID-19 on patients who survive but are incapacitated for months, Kang said.

The "quantification of this damage" how many people can't do manual labor or are so exhausted that they can't concentrate is key to understanding the full consequences of the disease.

"We haven't had a lot of diseases that have affected people on a scale like this," she said.

Read the rest here:
Virus may never go away but could change into mild annoyance - Sumter Item

Dr. Jill Rachbeisel, Appointed Chair Of The Department Of Psychiatry At The UM School Of Medicine – PRNewswire

BALTIMORE, Feb. 12, 2021 /PRNewswire/ -- University of Maryland School of Medicine (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today that Jill RachBeisel, MD, Associate Professor of Psychiatry, has been appointed to serve as the Chair of the Department of Psychiatry, effective immediately. Dr. RachBeisel has served as the Department's Interim Chair for the past two years and was previously Acting Chair and Vice Chair of the Department. A prominent leader at UMSOM, she has garnered tremendous support among faculty and staff for her efforts to forge partnerships among various entities in an effort to strengthen mental health services provided to patients and the community at large. Dr. RachBeisel will be named The Dr. Irving J. Taylor Endowed Professor and Chair, Department of Psychiatry, when she is invested March 18.

The appointment of Dr. RachBeisel was recommended by a Dean-appointed Review Committee led by Peter B. Crino, MD, PhD, Professor and Chair, Department of Neurology, and Rodney J. Taylor, MD, MPH, Professor and Chair, Department of Otorhinolaryngology-Head & Neck Surgery. After extensive review, the committee unanimously recommended to Dean Reece that she be considered for the permanent chair position.

For more than 20 years, Dr. RachBeisel has played an increasing role in leading the Department's clinical and academic activities, and in leading the integration of the UMSOM's Department's academic programs with the University of Maryland Medical System (UMMS), University of Maryland Medical Center (UMMC), as well as with the State of Maryland and City of Baltimore.

"Dr. RachBeisel is a tremendous leader and has had an enormous impact on the department during her terms as Interim Chair, Acting Chair, and Vice Chair. She has built lasting bridges between UMSOM and UMMS/UMMC, as well as bridges between UMSOM and the community at large which have benefitted greatly from her efforts to expand mental health services to those in need, " said Dean Reece, who is also Executive Vice President for Medical Affairs and the John Z. and Akiko K. Bowers Distinguished Professor. "She is highly respected across our academic community and has demonstrated unwavering and effective leadership throughout the years. Her gift for building partnerships between researchers and clinicians to create innovative and highly successful initiatives is remarkable and highly desirable."

Under her leadership as Interim Chair, Dr. RachBeisel has focused on building vital and lasting collaborations to strengthen the Department's infrastructure to support faculty growth and development, and the fusion of research and clinical agendas.

"Dr. RachBeisel is a phenomenally talented clinician, educator and mentor to our medical trainees and behavioral health specialists," said Bert W. O'Malley, Jr., MD, President and Chief Executive Officer of the University of Maryland Medical Center (UMMC). "She has been a guiding light and inspiration to our hospital staff during this stressful time of the global pandemic. Her passion for designing programs that span a spectrum of settings and for partnering with colleagues to provide integrated behavioral care expertise is invaluable."

The Department of Psychiatry received research and service grants totaling $43 million for fiscal year 2020 from the National Institutes of Health and elsewhere. Dr. RachBeisel worked with Dean Reece to establish the Vice Chair of Research and appointed Gloria Reeves, MD, Associate Professor of Psychiatry, to serve in this role. Other successful efforts include the establishment of the "Foundation Academy" to assist faculty in learning the intricacies of working effectively and successfully with non-profit foundations and to help prepare successful grant submissions. A newly established and formalized Mentoring Program for all new and mid-level faculty was also implemented to enhance faculty growth, professional development, and promotion leading to enhanced clinical and research success.

Dr. RachBeisel is the first woman to chair the UMSOM Department of Psychiatry. Immediately after assuming the interim chair position, Dr. RachBeisel established the Department of Psychiatry's Diversity, Equity, and Inclusion (DEI) Committee, chaired by Anique Forrester, MD, Assistant Professor of Psychiatry. The committee has focused on developing a training curriculum and diversifying the hiring of faculty and staff. They also have collaborated on efforts to retain new hires and maintain momentum to facilitate change. With support from a highly engaged faculty and resident group, Dr. RachBeisel also created a DEI lecture series that began last fall and will run through FY21.

"I am proud and honored to be taking the permanent helm of this department with its devoted faculty and staff," said Dr. RachBeisel. "Together we have risen to the challenges of the past year and have worked as a united team to sustain our programs and meet the increased needs of our patients and the campus workforce during the pandemic and the movement against racial injustice."

Heralded for her clinical achievements, Dr. RachBeisel helped spearhead the 2019 opening of two new state-of-the-art units-an adult inpatient behavioral health unit and the adult day hospital program at the University of Maryland Medical Center Midtown Campus (MTC). The programs, designed to optimize patient experience and safety, are led byStephanie Knight, MD, Assistant Professor of Psychiatry and Chief of Psychiatry at MTC. They are staffed by nurses, social workers, occupational and recreational therapists, addiction, counselors, and clinical nurse educators.

Dr. RachBeisel has also played a key role in developing a new partnership with other Baltimore area hospitals to strengthen and expand the crisis response infrastructure and community-based services to Baltimore City and its three surrounding counties. The Greater Baltimore Regional Integrated Crisis System (GBRICS) Partnership will enable UMMC to expand its Assertive Community Treatment (ACT) programs for adults and children, statewide tele-mental health program, and extensive addictions care program.

"Dr. RachBeisel has been instrumental in helping us develop and implement robust and evidence-based programs to provide expert, compassionate, team-based care for our community, including the citizens of West Baltimore, the City of Baltimore, and the region," said Alison Brown, MPH, President, University of Maryland Medical Center Midtown Campus. "We are so excited to have her continue permanently in this leadership role."

Serving as a faculty member in the Department of Psychiatry since 1989, Dr. RachBeisel began her career in the field of acute psychiatric care, emergency psychiatric interventions, and quality management in the hospital setting. She received her BS Degree in Chemistry and Mathematics from Carlow College in Pittsburgh, PA, and her RN Certification from the Western Pennsylvania School of Nursing. She then went on to complete her medical degree in 1985 from Pennsylvania State University School of Medicine. She completed her Psychiatric Residency Program at the University of Maryland Medical Center in 1989, serving as chief resident during her fourth year.

During her tenure at the UMSOM, Dr. RachBeisel has held numerous leadership positions at the Institute of Psychiatry and Human Behavior and served as the Division Director for Community Psychiatry at the University of Maryland Medical Center, overseeing 200 staff and physicians and providing a range of community mental health services. Through collaborations with the Division of Psychiatric Services Research, she became focused on the study of implementation of evidenced-based care for persons with a serious mental illness. In addition to her Division responsibilities, Dr. RachBeisel has been Chief of Clinical Services for the Department of Psychiatry since 2014, providing oversight of program development, performance improvement, and collaboration with the research divisions within the Department.

About the University of Maryland School of MedicineNow in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 45 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.2 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for nearly 2 million patients each year. The School of Medicine has more than $563 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents, and fellows. The combined School of Medicine and Medical System ("University of Maryland Medicine") has an annual budget of nearly $6 billion and an economic impact more than $15 billion on the state and local community. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu

About the University of Maryland Medical CenterThe University of Maryland Medical Center (UMMC) is comprised of two hospital campuses in Baltimore: the 800-bed flagship institution of the 14-hospital University of Maryland Medical System (UMMS) -- and the 200-bed UMMC Midtown Campus, both academic medical centers training physicians and health professionals and pursuing research and innovation to improve health. UMMC's downtown campus is a national and regional referral center for trauma, cancer care, neurosciences, advanced cardiovascular care, women's and children's health, and has one of the largest solid organ transplant programs in the country. All physicians on staff at the downtown campus are clinical faculty physicians of the University of Maryland School of Medicine. The UMMC Midtown Campus medical staff is predominately faculty physicians specializing in diabetes, chronic diseases, behavioral health, long term acute care and an array of outpatient primary care and specialty services. UMMC Midtown has been a teaching hospital for 140 years and is located one mile away from the downtown campus. For more information, visit http://www.umm.edu.

This news release was issued on behalf of Newswise For more information, visit http://www.newswise.com

SOURCE University of Maryland School of Medicine

Continue reading here:
Dr. Jill Rachbeisel, Appointed Chair Of The Department Of Psychiatry At The UM School Of Medicine - PRNewswire

Global Genomic Medicine Market Insights, Size Estimation, Research Insights, COVID-19 Impact and Future Trends By 2028 KSU | The Sentinel Newspaper -…

Global Genomic Medicine Market Report Provides Future Development Possibilities By Key Players, Key Drivers, Competitive Analysis, Scope, And Key Challenges Analysis. The Reports Conjointly Elaborate The Expansion Rate Of The Industry Supported The Highest CAGR And Global Analysis. This Report Providing An In Depth And Top To Bottom Analysis By Market Size, Growth Forecast By Applications, Sales, Size, Types And Competitors For The Creating Segment And The Developing Section Among The Global Genomic Medicine Market. Market Expansion Worldwide With Top Players Future Business Scope and Investment Analysis Report

Genomicmedicinemarket is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to grow at a CAGR of 9.70% in the above-mentioned forecast period. Increasing scientific research on genomic medicine is expected to create new opportunity for the market.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-genomic-medicine-market&pm

Genomic medicine is that part of the science which uses genomic information for the study of our DNA and their interactions with the health. They have the ability get the details about the typical biological information of an individual and use them to offer effective treatment.

Rising government investment in theprecision medicineis expected to drive the market growth. Some of the other factors such as increasing application area of genome, increasing number of genomics project and increasing usage for advanced sequencing in cancer pharmacogenomics & rare disorder diagnosis which will further accelerate the genomic medicine market in the forecast period of 2020 to 2027.

Dearth of awareness among healthcare providers, volatility in the regulation scenario and lack of adoption of genomic medicine will hamper the market growth.

Competitive Landscape and Genomic Medicine Market Share Analysis

Genomic medicine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to genomic medicine market.

The major players covered in the genomic medicine market report are BioMed Central Ltd, Cleveland Clinic., Genome Medical, Inc., Aevi Genomic Medicine, Inc., DEEP GENOMICS, Congenica Ltd., Editas Medicine, among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Global Genomic Medicine Market Scope and Market Size

Genomic medicine market is segmented of the basis of application and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-genomic-medicine-market&pm

Genomic Medicine Market Country Level Analysis

Genomic medicine market is analysed and market size insights and trends are provided by application and end user as referenced above.

The countries covered in the genomic medicine market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the genomic medicine market in the forecast period of 2020 to 2027. This is due to increasing R&D in the genomic medicine and availability of various universities offering education programs on genomic medicine.

The country section of the genomic medicine market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Genomic medicine market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipments, installed base of different kind of products for genomic medicine market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the genomic medicine market. The data is available for historic period 2010 to 2018.

Customization Available: Global Genomic Medicine Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @ Corporatesales@databridgemarketresearch.com

See the original post:
Global Genomic Medicine Market Insights, Size Estimation, Research Insights, COVID-19 Impact and Future Trends By 2028 KSU | The Sentinel Newspaper -...

Global Genetic Testing Market Insights, Size Estimation, Research Insights, COVID-19 Impact and Future Trends By 2028 KSU | The Sentinel Newspaper -…

Global Genetic Testing Market Report Provides Future Development Possibilities By Key Players, Key Drivers, Competitive Analysis, Scope, And Key Challenges Analysis. The Reports Conjointly Elaborate The Expansion Rate Of The Industry Supported The Highest CAGR And Global Analysis. This Report Providing An In Depth And Top To Bottom Analysis By Market Size, Growth Forecast By Applications, Sales, Size, Types And Competitors For The Creating Segment And The Developing Section Among The Global Genetic Testing Market. Market Expansion Worldwide With Top Players Future Business Scope and Investment Analysis Report

Global Genetic Testing Market, By Type (Predictive & Presymptomatic Testing, Carrier Testing, Prenatal & Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, Others), Technology (Cytogenetic Testing, Biochemical Testing, and Molecular Testing), Application (Cancer Diagnosis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, Others), Disease (Alzheimers Disease, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntingtons Disease, Rare Diseases, Other Diseases), Product (Equipment, Consumables), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028

Genetic testing market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to reach at an estimated value of 585.81 billion and grow at a CAGR of 11.85% in the above-mentioned forecast period. Increase in incidences of genetic disorders and cancer drives the genetic testing market.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-genetic-testing-market

The major players covered in the genetic testing market report are 23andMe, Inc., Abbott., Ambry Genetics., BGI, Biocartis, BIO-HELIX, bioMrieux SA, Blueprint Genetics Oy, Cepheid., deCODE genetics, GeneDx, Inc., Exact Sciences Corp, HTG Molecular Diagnostics, Genomictree., Illumina, Inc, Invitae Corporation, Laboratory Corporation of America Holdings, Luminex Corporation., ICON plc, Myriad Genetics, Inc, Natera, Inc., Pacific Biosciences of California, Inc, Pathway Genomics, QIAGEN, Quest Diagnostics Incorporated, F. Hoffmann-La Roche Ltd and Siemens Healthcare Private Limited among other domestic and global players.

Competitive Landscape and Genetic Testing Market Share Analysis

Genetic testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to genetic testing market.

Genetic tests are the type of tests which are defined as medical devices available in the form of kits and panels that are used for testing genetic diseases in humans. The testing is generally performed by collecting samples ofbloodfrom patients and the samples are then run on laboratory machines using test kits. There are numerous types of tests which are used in testing of genetic disorders which includes, predictive and presymptomatic testing, carrier testing, prenatal and newborn testing, diagnostic testing, pharmacogenomic testing among others.

Rise in awareness and acceptance of personalized medicines is the vital factor escalating the market growth, also rising advancements in genetic testing techniques, rising demand for direct-to-consumer genetic testing, rising consumer interest in personalized medicines in Europe, rising application of genetic testing in oncology and genetic diseases in North America and rising physician adoption of genetic tests into clinical care are the major factors among others driving the genetic testing market. Moreover, rising untapped emerging markets in developing countries and rising research and development activities in the machinery used inhealthcarewill further create new opportunities for genetic testing market in the forecasted period of 2021-2028.

However, rising standardization concerns of genetic testing-based diagnostics and rising stringent regulatory requirements for product approvals are the major factors among others which will obstruct the market growth, and will further challenge the growth ofgenetic testing marketin the forecast period mentioned above.

This genetic testing market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on genetic testing market contact Data Bridge Market Research for anAnalyst Brief,our team will help you take an informed market decision to achieve market growth.

For More Insights Get FREE Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-genetic-testing-market

Genetic Testing Market Scope and Market Size

Genetic testing market is segmented on the basis of type, technology, application, disease and product. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT GET FREE COVID-19 SAMPLE@ https://www.databridgemarketresearch.com/covid-19-impact/global-genetic-testing-market

Global Genetic Testing MarketCountry Level Analysis

Genetic testing market is analysed and market size insights and trends are provided by country, type, technology, application, disease and product as referenced above.

The countries covered in the genetic testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the genetic testing market due to rising demand for direct-to-consumer genetic testing and rising consumer interest in personalized medicines. Asia-Pacific is the expected region in terms of growth in genetic testing market due to rise in affordability, increasing surge in healthcare expenditure, and increase in awareness toward early screening of genetic disorders in this region.

The country section of the genetic testing market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Genetic testing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipments, installed base of different kind of products for genetic testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the genetic testing market. The data is available for historic period 2010 to 2019.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @Corporatesales@databridgemarketresearch.com

More:
Global Genetic Testing Market Insights, Size Estimation, Research Insights, COVID-19 Impact and Future Trends By 2028 KSU | The Sentinel Newspaper -...

I’m 28 and I Don’t Know My Family HistoryHere’s How That Affects My Health – msnNOW

Photo: Getty Images / Johner Images family medical history

If there's one thing I've learned over the years as a health and wellness writer, it's that information is power. The flip side of that is the fact that not having key information available to you can be deeply disempowering. Like millions of other Americans, I'm adopted, which means I haven't been able to find out a lot about important health information that most people have readily available to them: family health history and genetic health information.

Family health history is essentially just that: knowing the health histories of members of your biological family. This kind of information can help doctors pinpoint whether you are at risk for certain health conditions that can run in families or be determined by genetics. "Family history is a strong clue for chronic disease risks you may face, such as heart disease, stroke, cancer, and diabetes," says Latha Palaniappan, MD, the scientific director of Genomics and Pharmacogenomics in Primary Care at Stanford Medicine. The Centers for Disease Control and Prevention (CDC) CDC recommends documenting as much as you can about your family's health history in order to share with your doctor, and ask for additional testing if you're concerned about your risk for a specific disease.

While I've always valued a healthy lifestyleI try to eat well, sleep enough, exercise, and manage stress as much as possibleI've wondered recently if my inclination towards healthy living has been driven in part by fear, specifically the fear of what I don't know about my health and genetics. Since I don't know what could be in my genes, at least I do have some control over my lifestyle now, and that counts for a lot, right?

Thankfully, Dr. Palaniappan assures me that family history is not the end-all, be-all of what will happen with your health."Family history is probabilistic, not predictive," she says. (Basically, it can educate you about your odds of experiencing a certain health outcome, but not predict it outright.) But if you do have access to that information, use it, since "family history provides important clues about your health risks," says Dr. Palaniappan.

So if you don't have access to this information, should you be worried? And what else can you do, besides actually going out to try to find your biological relatives' information (which is a hugely personal choice, and not possible for some)? There are some other things you can do to help you gather more information about your health and feel more empowered about your future.

Honestly, I didn't think about my family health history too much until I started approaching 30. As the mystery surrounding family health information came up a bit more for me, I talked to my mom and my sister about my concerns surrounding what we don't know. When my mom got me a 23andMe DNA test (which start at $199 for the Health + Ancestry test) for Christmas one year, I was excitedand kind of anxiousto have the chance to take a deeper look into my health information.

23andMe is just one example of a direct-to-consumer (DTC) DNA test that can give you some more information about your health. According to the company's website, the health reports available with the test include genetic information that can clue you in to your genetic risk for conditions like type 2 diabetes, select variants of BRCA1/BRCA2 (the gene associated with breast, ovarian, and pancreatic cancer), celiac disease, uterine fibroids, and more. The brand's test can tell you about your carrier status (meaning if you carry genes linked to an inherited disease that could affect your children) for some diseases like cystic fibrosis and sickle cell anemia.

Gallery: Sure Signs You've Already Had COVID, Says Dr. Fauci in New Report (ETNT Health)

However, these DTC tests don't often come with specific consultation to walk you through what's present in your genome and how that translates into actual risk. That's why it's important to work with a genetics expert or genetic counselor if you can, says Robert C. Green MD, a medical geneticist who leads the Preventative Genomics Clinic at the Harvard-affiliated Brigham and Women's Hospital, and is the director of the Genomes2People Research Program."You [can] have a geneticist or genetic counselor who basically talks to you about what [the test results] mean and what should you do about it. What should you worry about and what should you not worry about," says Dr. Green. For example, if you tested positive for the gene for a certain hereditary cancer, a genetic counselor can help you with the next steps, like if you should seek more testing or work with a specialist.

Dr. Green adds that DTC tests aren't the most comprehensive testing option. That's because most of them use what's called chip-based DNA technology, which essentially scan your genome for known common mutations or markers along your genome, he says. "[This technology] can be very good for ancestry for [finding relatives] and for certain specific markers, such as the Ashkenazi Jewish BRCA1 mutation that 23andMe looks for. It does not look at every letter in your genes, and it's not typically set up to find rare or novel mutations that can affect your health." (They're not always super accurate, eithera 2019 study found that these chips have a very high false-positive rate for rare genetic mutations.) "For health reasons sequencingwhich looks at every letter in a segment of your genome or across the whole genomeis more expensive, but much, much more comprehensive," he says.

DNA testing is definitely not cheap (it can run anywhere from $200 up to $2,000 for the more in-depth testing, and isn't always covered by insurance) and it's certainly not the only way to find out more information about your health.

If you don't know much about your family health history, Dr. Palaniappan encourages paying attention to key health markers including blood pressure, cholesterol, glucose, and heart rate, and getting those checked regularly. "These measurable risk factors can be effectively treated to reduce your risk of heart disease, stroke and diabetes," says Dr. Palaniappan. "Everyone can reduce the risk of disease by eating a healthy diet, getting enough exercise, and not smoking. Cancer screening tests such as mammograms and colorectal cancer screening can detect precancer and treatable cancers early," she says.

While getting the DNA test felt like a great first step to knowing more about my health, it's also good to know that the everyday things that I sometimes don't even think about (like walking my dog) might have a bigger impact on my health than I thought before."What you do each and every daywhat you eat, how much you exercise, and your other health behaviors, can ultimately affect your risk of developing disease," says Dr. Palaniappan. If anything, I've learned that not knowing your family health history doesn't have to be a huge blank spot, but if I ever do want to know more, there are optionswhich is empowering for sure.

Oh hi! You look like someone who loves free workouts, discounts for cult-fave wellness brands, and exclusive Well+Good content. Sign up for Well+, our online community of wellness insiders, and unlock your rewards instantly.

See the original post:
I'm 28 and I Don't Know My Family HistoryHere's How That Affects My Health - msnNOW

Global Companion Diagnostic Markets Report 2021: A Steep Growth Curve Interrupted by COVID-19 – Forecast to 2025 – ResearchAndMarkets.com – Galveston…

DUBLIN--(BUSINESS WIRE)--Feb 12, 2021--

The "Companion Diagnostic Markets - the Future of Diagnostics, by Funding Source and Application with Customized Forecasting/Analysis, COVID-19 Updates, and Executive and Consultant Guides 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Will Personalized Companion Diagnostics become the norm for diagnostics?

Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is finally moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing. Find out the latest outlook for this important market.

Learn all about how diagnostic players are jockeying for position with their pharmaceutical counterparts and creating new and significant business opportunities. And some players are already taking the lead. It is a dynamic market situation with enormous opportunity. Diagnostic companies are trying to back the right horse. The science is racing forward. And the cost of molecular diagnostics continues to fall.

Key Topics Covered:

Companion Diagnostic Market - Strategic Situation Analysis

1. Introduction and Market Definition

1.1 What are Companion Diagnostics?

1.2 The Personalized Medicine Revolution

1.3 Market Definition

1.4 Methodology

1.5 A Spending Perspective on Clinical Laboratory Testing

2. Market Overview

2.1 Players in a Dynamic Market

2.1.1 Academic Research Lab

2.1.2 Diagnostic Test Developer

2.1.3 Instrumentation Supplier

2.1.4 Distributor and Reagent Supplier

2.1.5 Independent Testing Lab

2.1.6 Public National/regional lab

2.1.7 Hospital lab

2.1.8 Physician Office Labs

2.1.9 Audit Body

2.1.10 Certification Body

2.2 Personalized Medicine and Companion Diagnostics

2.2.1 Basics

2.2.2 Method

2.2.3 Disease risk assessment

2.2.4 Applications

2.2.5 Diagnosis and intervention

2.2.5.1 Companion Diagnostics

2.2.6 Drug development and usage

2.2.7 Respiratory proteomics

2.2.8 Cancer genomics

2.2.9 Population screening

2.2.10 Challenges

2.2.11 Regulatory oversight

2.2.12 Intellectual property rights

2.2.13 Reimbursement policies

2.2.14 Patient privacy and confidentiality

2.3 Chromosomes, Genes and Epigenetics

2.3.1 Chromosomes

2.3.2 Genes

2.3.3 Epigenetics

2.4 Cancer Genes

2.4.1 Germline vs Somatic

2.4.2 Changing Clinical Role

2.5 Structure of Industry Plays a Part

2.5.1 New Pharmaceutical Funding Market

2.5.2 Economies of Scale

2.5.2.1 Hospital vs. Central Lab

2.5.3 Physician Office Labs

2.5.4 Physicians and POCT

3. Market Trends

3.1 Factors Driving Growth

3.1.1 Level of Care

3.1.2 Immuno-oncology

3.1.3 Liability

3.1.4 Aging Population

3.2 Factors Limiting Growth

3.2.1 State of knowledge

3.2.2 Genetic Blizzard.

3.2.3 Protocol Resistance

3.2.4 Regulation and coverage

3.3 Instrumentation and Automation

3.3.1 Instruments Key to Market Share

3.3.2 Bioinformatics Plays a Role

3.4 Diagnostic Technology Development

3.4.1 Next Generation Sequencing Fuels a Revolution.

3.4.2 Single Cell Genomics Changes the Picture

3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment

3.4.4 CGES Testing, A Brave New World

3.4.5 Biochips/Giant magneto resistance based assay

4. Companion Diagnostics Recent Developments

4.1 Recent Developments - Importance and How to Use This Section

4.1.1 Importance of These Developments

4.1.2 How to Use This Section

5. Profiles of Key Players

6. The Global Market for Companion Diagnostics

6.1 Global Market Overview by Country

6.2 Global Market by Application - Overview

6.3 Global Market Funding Source - Overview

7. Global Companion Diagnostic Markets - By Application

7.1 Oncology

7.2 Neurology

7.3 Cardiology

7.4 Other Application

8. Global Companion Diagnostic Markets - Funding Source

8.1 Global Market Pharmaceutical

8.2 Global Market Venture

8.3 Global Market Clinical

8.4 Global Market Other Funding

For more information about this report visit https://www.researchandmarkets.com/r/f07ek

View source version on businesswire.com:https://www.businesswire.com/news/home/20210212005208/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

Link:
Global Companion Diagnostic Markets Report 2021: A Steep Growth Curve Interrupted by COVID-19 - Forecast to 2025 - ResearchAndMarkets.com - Galveston...

Does Red Wine Have Any Effect on Weight Loss? – Healthline

Red wine is the alcoholic drink of choice for many people, and its gotten a lot of buzz for its potential health benefits.

The drink, made from fermented red grapes, is loaded with antioxidants, but it can also be full of calories and sugar.

If youre trying to lose weight, you may be wondering if red wine could help you or if it would just be a hindrance.

This article reviews red wines nutrient content, what the evidence says about red wine and weight control, and how you can enjoy red wine while still losing weight.

A 5-ounce (148-mL) serving of red wine contains (1):

Most of the calories in red wine come from alcohol, which provides seven calories per gram, and the remainder comes from carbs (2).

Keep in mind that there are several different types of red wine, all with varying amounts of alcohol and sugar content, which will affect their total calorie count. Additionally, there will be some variation among brands.

A 5-ounce (148-mL) serving of red wine contains 125 calories, mostly from alcohol and carbs. There will be some variation among types and brands of red wine.

Several studies have assessed the link between alcoholic beverages and weight.

When it comes to weight management, there appear to be both pros and cons to drinking red wine.

Red wine is rich in resveratrol and other antioxidants that may benefit blood sugar control, heart health, and inflammation. Additionally, moderate wine consumption may help protect against excess weight gain (2, 3).

Red wine and other flavonoid-rich foods like olive oil, nuts, fruits, and legumes are considered staple foods in the Mediterranean-style diet, which has been associated with better weight control than a standard American diet (4, 5).

Unfortunately, evidence on the effects of red wine itself is fairly mixed. Some animal studies have found that red wine consumption decreases body weight and body fat levels, but others have found the opposite (6, 7, 8).

Additionally, a study in 29 people with obesity found that red wine antioxidants appeared to not affect blood sugar control (9).

However, other human studies have noted that moderate alcohol consumption may help improve blood sugar control potentially making it easier to manage weight (10, 11).

More research is needed before the effects of red wine on weight control are fully understood.

Several studies have noted that excess alcohol consumption is linked to weight gain especially in men (2, 12, 13).

Alcohol contains more calories per gram than carbs and protein, and many alcoholic beverages like beer, wine, and mixed drinks may also be loaded with sugar.

Because of this, it can be easier to consume more calories than you intend to when drinking alcohol (2, 14, 15).

Additionally, overconsumption of alcohol may lead to insulin resistance and blood sugar control problems, which may be a precursor to weight gain and type 2 diabetes (16).

Note that 5 ounces (148 mL) of wine is considered 1 serving, and moderate drinking is defined as no more than 2 servings of alcohol per day for men and 1 serving of alcohol per day for women (15).

Red wine is rich in the antioxidant resveratrol, but research is mixed regarding its positive weight effects. Excess alcohol consumption including red wine may lead to weight gain.

Luckily, you dont have to completely avoid drinking red wine if youre trying to lose weight.

Here are some ways that you can enjoy red wine without hindering your weight loss efforts:

As long as youre watching your portion sizes and drinking in moderation, wine shouldnt have a huge effect on your weight.

Additionally, if you notice that your weight loss is slowing down and nothing has changed except the amount or frequency of your red wine intake, try cutting back to see if that helps.

You can drink red wine and still lose weight as long as you limit how much you drink and track your calories.

Red wine is rich in antioxidants, but its also full of calories from alcohol and carbs. This makes it a mixed bag when it comes to weight loss.

Too much red wine, or any alcoholic drink, may hinder weight loss and contribute to weight gain. That said, red wine in moderation may provide some protective effects against weight gain.

To enjoy red wine while losing weight, make sure to stick to a single serving, avoid sugary dessert wines, and track your calories.

Original post:
Does Red Wine Have Any Effect on Weight Loss? - Healthline

Chocolates are fun, but your heart needs better help than that – pentictonherald.ca

Valentines Day, the largest chocolate and flower day of the year happens tomorrow. Youre welcome to all the gents reading this, you've still got time to pick up something for your sweetheart.

In addition to flowers, chocolate, wine and heart-shaped pizzas, paradoxically February is also heart-health month. As much as wed like to believe consuming a box of dark chocolates and a bottle of red wine after dinner can be good for the heart, the palette is by far the body part experiencing the greatest benefits.

Now, before you all go labelling me as anti-chocolate and no fun, I am a chocolate lover. In fact Ive created several chocolate recipes that are not only delicious, but healthy. Something Ive been able to share and help my clients stay on track with their health goals and not feel deprived. And on the rare occasion, Ill have a glass of red wine.

Dark chocolate and red wine both contain resveratrol, a component that does promote heart health. What most people dont know however, is that the amount of resveratrol youd ingest over dessert with your sweetheart, isnt enough to make a significant difference in your health.

As youve heard (or read) me say before, we can get all the nutrients our body needs from food. Theres no question God gave us great stuff here on this planet. The question is, do we? An article published by the Kressler Institute in 2018 reported, More than half the calories Americans consume, come from nutrient-depleted, ultra-processed foods... and went on to say that Nearly one-third (31%) of the U.S. population is at risk for at least one vitamin deficiency or anemia.

United States stats are always easier to dig up, but trust me, Canadians are right there too.

Since were smack dab in the middle of heart month, let's look at three supplements that are known for building and supporting a healthy heart. Ive already mentioned resveratrol. Coenzyme Q10 or CoQ10, and Omega 3.

As with any nutrient, taking a supplement should not be considered a replacement for the healthy foods that also contain the same nutrients. Supplements are to come alongside and fill the gaps, not provide a get-out-of-eating-your-veggies free card.

Of these three, if you take supplements at all, you're most likely using, or at least have heart of, omega 3s. Several types of fish including salmon, lake trout, sardines, herring, anchovies, as well as nuts, seeds, flaxseed, and chia all contain omega 3 fatty acids. Great for supporting brain function, alleviating rheumatoid arthritis, and joint pain, omega 3s also help to lower blood fat levels.

In other words, omega 3s help bring down elevated triglycerides and lowers cholesterol, which also brings down your risk of heart disease and stroke. And unless youre eating fish daily, supplementing is definitely a good idea.

Resveratrol, found in red grapes and cocoa beans red wine and dark chocolate is known for its antioxidant properties and a 2015 review posted on PubMed concluded high doses may help reduce the pressure exerted on artery walls when the heart beats, bringing down blood pressure.

Of course, consuming high doses of red wine or chocolate for that matter would produce the opposite effect, creating inflammation. So, supplementing is the way to go.

Researchers also found supplementing with resveratrol had a positive impact on overall cholesterol levels and may also help decrease plaque buildup inside

Unlike resveratrol and omega 3, Coenzyme Q10, or CoQ10, is something our bodies produce naturally.

According to a June 2019 article by Dr. Josh Axe, CoQ10 helps cells produce energy and neutralize free radicals, the damaged cells that cause illness and aging, improve heart health.

It offsets negative effects of statin drugs, slows down DNA damage due to aging, helps maintain ph balance, may slow or reverse the spread of some cancers, supports cognitive function, may improve male infertility, treats symptoms of fibromyalgia.

The amount of CoQ10 our bodies produce reduces with age. And although consuming foods that contain CoQ10 such as meats, poultry, fish, eggs, beans and nuts is something everyone should be doing, Dr. Axe goes on to say that for people who, struggle with certain health conditions, such as heart disease having chronic diseases, high levels of stress, deficient in vitamin B, mitochondria diseases, taking statin drugs, food alone may not be enough as these conditions further impede CoQ10 production.

And as the heart is just one of many areas CoQ10 is needed for optimal health, it's in our best interest to keep those levels up.

As with anything you put in your body, quality matters. Like your car, the better quality fuel you put in, the better performance youre going to get. Whether its food or supplements, same goes for your body. And in case there was any doubt, that old adage you get what you pay for, is true.

Februarys the perfect time to give your heart and yourself some love. Youre worth it.

Tania Gustafson is a nutritionist and fitness coach.

On the web: fuelignitethrive.com.

Email: tania@fuelignitethrive.com. Find healthy chocolate recipes at the 8 Weeks is All it Takes group on Facebook.

Follow this link:
Chocolates are fun, but your heart needs better help than that - pentictonherald.ca

Trans Resveratrol Market Expected to Witness the Highest Growth – The Courier

The latest report on Trans Resveratrol Market provides an overall assessment of the world market Trans Resveratrol by classifying it into terminal applications, types, and regions. The report presents a comprehensive analysis of the competitive landscape and strategies that have positively influenced the market. Furthermore, the report provides an overview of current market dynamics by looking at different key segments based on product, types, applications, end-to-end industries, and market scenario.

Get a Sample PDF of the report https://www.regalintelligence.com/request-sample/207288

Leading Essential Players of Trans Resveratrol Market Report:

Trans Resveratrol Market segments by product type taking into account output, turnover (value), price trends:

Market segment by applications that take consumption growth rate and market share into consideration:

Scope/Extent of the Trans Resveratrol Market Report:

The Trans Resveratrol market research report concentrates on the analysis of demand and supply at the regional and national global level. From a global perspective, the report presents Trans Resveratrol markets per size, analyzing historical data and future perspectives. The report focuses on a number of key areas, including North America, Europe, Asia-Pacific and the West.

2019 has been considered the base year and the report provides a market estimate for 2020-2026. The report looks at the world market for the Trans Resveratrol (size, capacity, production, and consumption) in key regions.

Do not hesitate to consult our analyst prior to purchasing the report at https://www.regalintelligence.com/enquiry/207288

Additionally, in the Trans Resveratrol market research reports, the following points are included with an in-depth review of each point:

Table of Contents

Chapter 1: An overview of the market includes the definition, specifications, and classification of the market Trans Resveratrol, characteristics, scope, and applications.Chapter 2: Analysis of product costs and prices: structure of manufacturing costs, cost of raw materials and suppliers, manufacturing process, the structure of the industrial chain.Chapter 3: Market demand and supply analysis which includes commercial production capacity and date, distribution of manufacturing plants, R&D status, and technology source, analysis of raw material sources.Chapter 4: Forces that keep the marketplace going.Chapter 5 and 6: Regional Market Analysis that includes North America, Europe, China, Japan, Southeast Asia, and India, Trans Resveratrol Market Analysis (by Type).Chapter 7 and 8: Industrial structure, Demand, and Supply Gap Analysis.Chapter 9: Market Trend Analysis, Regional Market Trend, Market Trend according to Product Type.Chapter 10: Trans Resveratrol Turnover Channels, Distributors, Retailers, Dealers, Research Findings and Conclusion, Appendix along with Data Source.

For Detail Report@ https://www.regalintelligence.com/buyNow/207288

Thank You.

The rest is here:
Trans Resveratrol Market Expected to Witness the Highest Growth - The Courier

What Happens To Your Body When You Eat Grapes | Eat This Not That – Eat This, Not That

As far as healthy snacks go, it doesn't get much better than grapes. They're super convenient to pack and take with youand they taste good, to boot. Best of all, they're about 84% water. Simple, meaning you get an instant dose of hydration from munching on them. Grapes come in literally thousands of different varieties and colors, all of them delicious in their own unique way. But what happens to your body when you eat grapes? Well, a lot of things. While grapes offer a bevy of health benefits, they can also do more harm than good if you go overboard with your snackingwhich, let's be honest, is pretty easy to do with this fruit.

A 1-cup serving of red or green grapes contains 28% of your daily recommended intake for vitamin K, a nutrient that's essential for bone and heart health. Not only that, but they're extremely low in fat, sodium, and cholesterol, and an excellent source of vitamin C. Studies have shown that eating grapes doesn't just support your physical health, but also your cognitive health, too: One 2017 studyfound that when adults took a grape supplement daily, they improved their test scores for attention, memory, and language. That said, grapes are also high in sugar and carbs, and low in protein.

Grapes are incredibly versatileyou can snack on them right off the vine, incorporate them into smoothies, toss them into salads, or even freeze them for a popsicle-like treat. Now, if you're curious about what happens to your body when you eat grapes, read on. And for more healthy tips, be sure to check out our list of The 7 Healthiest Foods to Eat Right Now.

Grapes pack a whopping 23 grams of sugar per cup.However, certified nutritionist Paul Claybrook, MS, notes that this fruit is relatively low on the glycemic index, meaning they shouldn't cause your blood sugar to spike too much if you eat them in moderation.

"Your blood sugar will increase but not as significantly as something like soda would cause," he explains. "Part of the reason for this is that grapes contain some fiber, which slows down the speed at which your body can absorb nutrients, including sugar. There isn't a whole lot of fiber (just under a gram per cup) but it's enough to keep your blood sugar in a reasonable range as long as you aren't pigging out on them."

Grapes also contain a compound called resveratrol, which research has shown may increase insulin sensitivity, thus having a beneficial effect on your blood sugar levels.

Studies even say that Controlling This Hormone May Help Lower Blood Sugar.

You've heard of antioxidants, right? Those powerful substances that defend your body from free radical damage? Well, grapes are chock-full of them, and they can help protect and repair your cells from oxidative stresswhich is linked to the development of chronic diseases like cancer, heart disease, and diabetes.

"Oxidative stress simply means that there are too many free radicals (waste products) and not enough antioxidants (waste neutralizers) in your body to mop them up," explains Claybrook. "The result is damage to tissues that can lead to disease. Fortunately, grapes contain tons of antioxidants including flavonoids, phenolics, vitamin C, quercetin lutein, beta carotene, and resveratrol."

Research has revealed that grapes contain over 1,600 beneficial plant compounds, and since the highest concentration of antioxidants is in the seeds and the skin, it's better to eat them whole than simply drink grape juice. Additionally, it's also worth noting that red grapes are higher in antioxidants than green ones because they contain anthocyanins, a type of flavanoid that's responsible for their color.

Get even more healthy tips straight to your inbox by signing up for our newsletter!

Chronic inflammation can cause a number of long-term symptoms and health issues, including muscle aches and joint pain, weight gain, headaches, fatigue, and gastrointestinal problems. It's also been linked to cancer, heart disease, Alzheimer's, type 2 diabetes, arthritis, and other serious conditions.

Luckily, according to Claybrook, the diversity of powerful antioxidants found in grapes can help to reduce inflammation in the body. Specifically, resveratrol is known to have anti-inflammatory properties. Multiple studieshave found that taking grape powder extract can increase the levels of anti-inflammatory compounds in your blood.

Here are Instant Ways to Reduce Your Inflammation, According to a Doctor.

"While grapes are very healthy, too much of a good thing can still be a problem," says Claybrook.

If you were to eat, say, 2 cups of grapes, you'd be getting almost 47 grams of sugarthat's almost the equivalent of two candy bars.

"Sugar causes weight gain, so you don't want to eat grapes by the pound," adds Claybrook. "Grapes could also cause gas, bloating, diarrhea, and an upset stomach if you overdo it."

One serving is about 1/2 cup or 16 grapeswhich may seem small, but controlling your portion sizes of this fruit will allow you to reap the benefits without the risks of digestive issues and weight gain.

One cup of grapes contains an impressive 288 milligrams of potassium, which plays a key role in lowering blood pressure. Not only that but studies have shown that red grapes contain compounds that may help to reduce total and "bad" LDL cholesterol.

"The polyphenols in grapes have been shown to lower the risk of atherosclerosis (hardening of the arteries)," adds Claybrook. "They do this of course by eliminating free radicals but also improve the function of the tissues and help avoid LDL cholesterol from being damaged and sticking to blood vessel walls. They also help maintain the elasticity of blood vessels, thus reducing blood pressure and keep platelets from sticking together and creating clogs."

Here are 17 Foods That Lower Cholesterol.

Grapes are a stellar source of vitamin C, packing 27% of the RDI in 1 cup. As you may or may not know, vitamin C is an essential nutrient that benefits your immune system, which may explain why test-tube studies have shown that grape skin extract can protect against the flu virus.

In fact, 2013 research that compared the immune-boosting effects of hundreds of foods found that red grapes stood outmainly due to the resveratrol, which works with vitamin D to raise the expression of a specific gene involved in immune function.

Here are 8 Ways to Support a Healthy Immune System, According to Harvard.

Original post:
What Happens To Your Body When You Eat Grapes | Eat This Not That - Eat This, Not That

Global Resveratrol Market Report 2020 Industry Trends, Share and Size, Expected CAGR, Top Manufacturers and Consumer Analysis across the Region and…

Resveratrol Market Overview

The report study researched by Adroit Market Research gives comprehensive knowledge and valuable insights about the Resveratrol Market. Also, the study attempts to deliver significant and detailed insights into the current market prospect and emerging growth scenarios. The report on the Resveratrol Market also emphasizes on market players as well as the new entrants in the market landscape.

The Resveratrol Market report is a precise and deep-dive study on the current state that aims at the major drivers, market strategies, and imposing growth of the key players. Worldwide Resveratrol Industry also offers a granular study of the dynamics, segmentation, revenue, share forecasts, and allows you to make superior business decisions. The report serves imperative statistics on the market stature of the prominent manufacturers and is an important source of guidance and advice for companies and individuals involved in the Resveratrol industry.

Get Sample PDF Brochure (including full TOC, Tables, & Figures) of Resveratrol Market @ https://www.adroitmarketresearch.com/contacts/request-sample/503?utm_source=bh

By Geographical Regions

Asia Pacific: China, Japan, India, and Rest of Asia Pacific Europe: Germany, the UK, France, and Rest of Europe North America: The US, Mexico, and Canada Latin America: Brazil and Rest of Latin America Middle East & Africa: GCC Countries and Rest of Middle East & Africa

Highlights of the Report:

Accurate market size and CAGR forecasts for the period 2019-2026 Identification and in-depth assessment of growth opportunities in key segments and regions Detailed company profiling of top players of the global Resveratrol Market Status and Trend Analysis 2019-2026 (COVID-19 Version) Exhaustive research on innovation and other trends of the global Resveratrol Market Status and Trend Analysis 2019-2026 (COVID-19 Version) Reliable industry value chain and supply chain analysis Comprehensive analysis of important growth drivers, restraints, challenges, and growth prospects

Competitive Analysis:

The Resveratrol industry company profile section of the report includes their basic information like website, legal name, market position, and headquarters, top competitors by market revenue or capitalization, and past background together with contact information.

The competitive evaluation of the application market brings monitoring into the product usage types of the current top players. Also, the study focusses on characteristic features & Resveratrol price, valuable reviews on the crucial products in the global market. The report offers key facts and figures on the Resveratrol market statistics, key competitors and is a significant source of guidance and business direction and an individuals interests in the Resveratrol industry.

Some of the Important and Key Players of the Global Resveratrol Market:

Jeunesse Global, DSM Nutritionals, Sirtris Pharmaceuticals Inc., Ltd., Resveratrol Enhanced Pty Ltd, Hill Pharmaceutical Co., Andorra Life, Terraternal, ResVitale LLC, Endurance Products Company, ASN Pharmaceutical LLC, Xieli Pharmaceutical, RevGenetics, GlaxoSmithKline and Evolva among others.

Complete Summary with TOC Available @ https://www.adroitmarketresearch.com/industry-reports/resveratrol-market?utm_source=bh

The report provides market size with 2019 as the base year in consideration and a yearly forecast until 2025 in terms of Revenue (USD Million). The estimates for all segments including type and application have been provided on a regional basis for the forecast period mentioned above. We have implemented a mix of top-down and bottom-up approaches for market sizing, analysing the key regional markets, dynamics, and trends for various applications.

The report of Resveratrol Market studies the key players present in the market. The chapter includes the competitive landscape section which provides the full and in-depth analysis of the current market trends, changing technologies, and developments that will be beneficial for the companies, which are competing in the market. The report offers an overview of revenue, demand, and supply of data, futuristic cost, and growth analysis during the projected year. In addition to a brief overview of the company, analysts shed light on their valuation and evolution. It also discusses the list of important products and the ones in the pipeline. The competitive landscape is analysed by understanding the approaches of the companies and the initiatives they have taken in recent years to triumph over the intensive competition.

Resveratrol Market Segmentation

Type Analysis of Resveratrol Market:

Form Segment, (Liquid supplements,Powdered form,Red wine pill), Type Segment, (Grape seed extract,Natural resveratrol,Japanese knotweed extract), Distribution channel Segment, (Drug stores,Departmental stores,Hypermarket/supermarket,Online stores,Others)

Applications Analysis of Resveratrol Market:

Application Segment, (Cosmetics,Pharmaceuticals,Dietary supplements,Others)

Reasons for Purchasing Resveratrol Market Report:

This report provides pin-point evaluation for changing competitive dynamics of Resveratrol market It supplies a forward-looking viewpoint on Various factors driving or restraining keyword market growth It supplies an eight-year forecast assessed based on the way the Resveratrol market is predicted to increase This will help in knowing the key product segments along with their future It provides pin point evaluation of altering competition dynamics and keeps you ahead of competitors This will help in making informed business decisions by having complete insights of Resveratrol market and by making in-depth evaluation of Resveratrol market segments

Key benefits to buy this report: What are the key market trends? What are the market dynamics? What are the constraints on category growth? What are the category growth drivers? What are the demand-supply shifts? Who are the suppliers in this market?

Table of Contents: Resveratrol MarketChapter 1. Resveratrol Market OverviewChapter 2: State of the World Market and Forecasts by RegionChapter 3: State of the World Market and Forecast by TypeChapter 4: Global Market State and Prospects for the Downstream SectorsChapter 5: Analyzing Market DriversChapter 6: The State of Market Competition of Major ProducersChapter 7: Major Producers and Market DataChapter 8: Exploration and Production Market AnalysisChapter 9: Cost and Gross Profit AnalysisChapter 10: Analyzing Marketing Status

For any queries get in touch with Industry Expert @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/503?utm_source=bh

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a Markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable Market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

More here:
Global Resveratrol Market Report 2020 Industry Trends, Share and Size, Expected CAGR, Top Manufacturers and Consumer Analysis across the Region and...